Lumida
/BTMD
⌘K
Biote Corp

Biote Corp

BTMD
$2.43USD↑+2.10%+0.05 today

MARKET CAP

91.3M

P/E (TTM)

4.7x

FWD P/E

8.4x

DAY RANGE

$2 – $3

52W RANGE

$1
$5

AI Summary

Stalk
StalkMedium

BTMD has transitioned into a confirmed Stage 2 advance after breaking above multi-month resistance, but with price extended above rising EMAs and 50 DMA into extreme overbought, we will wait for a constructive pullback into the 9 EMA, 21 EMA, and 50 DMA support zone before adding exposure, consistent with our Free Cash Flow + Buybacks strategy and mindful that failure to hold these levels would undermine the medium-term bullish structure.

  • ↑FY26 revenue guidance above $190M indicates procedural recovery post-recall
  • ↑Dietary supplement revenue up 30% YoY to $11M, driven by e-commerce
  • ↓Q1 revenue fell 8.3% YoY to $44.9M, with procedure rev down 13.2%
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

BioT Corp. (NASDAQ: BTMD) is a pioneering organization in the hormone optimization and therapeutic wellness space, focused on developing innovative solutions for improving health outcomes through its network of clinics. Positioned as a leader in personalized hormone therapy, BioT targets significant growth potential in an underserved market with its bioidentical hormone therapies and dietary supplements. The company is currently navigating operational challenges, including a product recall, while striving to enhance its commercial capabilities and maintain a robust provider network.

Bull says

  • ↑FY26 revenue guidance above $190M indicates procedural recovery post-recall
  • ↑Dietary supplement revenue up 30% YoY to $11M, driven by e-commerce
  • ↑Sales force expanded from 90 to 120 reps, boosting clinic recruitment
  • ↑High earnings yield and robust profit margins suggest strong value
  • ↑Positive analyst revisions reflect growing confidence in earnings
  • ↑Pent-up demand post-recall could drive procedure volume rebound

Bear says

  • ↓Q1 revenue fell 8.3% YoY to $44.9M, with procedure rev down 13.2%
  • ↓Voluntary recall cut ~$1.7M in procedure revenue, pressuring near-term growth
  • ↓Clinic attrition around 8% could hinder network expansion and sales
  • ↓Low institutional ownership signals liquidity risk and investor skepticism
  • ↓Regulatory compliance risks persist from ongoing FDA recall engagement
  • ↓Intense competition from GLP-1 therapies and telehealth peers raises threat

Investment themes with BTMD

Health Care Providers↑ +0.29%

HCA · DGX · UHS

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026neutral

Transcript signals

Bull points

  • Dietary supplement revenue grew 19.1 percent to $11.0 million. The increase was primarily driven by the continued growth of our e-commerce channel.
  • we expect our second quarter product mix will continue to include an elevated level of third-party supply which will impact second quarter gross margin.
  • We maintain our guidance, forecasting 2026 revenue above $190 million and 2026 adjusted EBITDA of greater than $38 million.

Bear points

  • Revenue decreased 8.3% to $44.9 million, with procedure revenue declining 13.2% to $31.3 million, which included a $1.7 million impact related to the voluntary recall of certain hormone pellets shipped by Asteria Health.
  • The decrease was primarily due to $1.1 million of incremental cost related to the recall.
  • Net income for the first quarter of 2026 included a gain of $2.1 million due to changes in the fair value of the earn-out liabilities. By comparison, net income for the first quarter of 2025 included a gain of $10.7 million due to changes in the fair value of the earn-out liabilities.
Read full transcript analysis ›